Literature DB >> 27222134

P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas.

Banu Sarsik1, Basak Doganavsargil2, Adnan Simsir3, Ayse Yazici4, Burcin Pehlivanoglu5, Cag Cal3, Sait Sen2.   

Abstract

p21 and p27 are members of cyclin-dependent kinase family, which function as tumor suppressors and they are involved in development and progression of several malignancies. We investigated their expression in upper urinary tract urothelial carcinoma (UUTUC). Radical nephroureterectomy materials of 34 patients were assessed by immunohistochemistry to evaluate expression of p21 and p27 in UUTUC. Results were correlated with various clinicopathological variables as age, gender, tumor grade and stage, tumor architecture, multifocality, subsequent bladder carcinoma development and clinical outcome.p21 and p27 expression was observed in 52.9 % (n = 18) and 88.2 % (n = 30), respectively. A total of 21 tumors (61.7 %) showed either total loss of p21 expression (n = 16, 47 %) or lower expression (n = 5, 14.7 %). No correlation was found between p21 expression and clinicopathologic variables. Cases showing total loss or lower p27 expression (11.7 % and <25.6 %, respectively) (n = 19, 55.8 %) constituted 67.6 % (n = 23) of the cases totally. This loss or lower p27 expression correlated with a shorter overall survival in both univariate and multivariate analysis (p = 0.039 and p = 0.037, respectively). None of the noninvasive tumors (papillary and nodular tumors) showed loss of p27 (p = 0.016) while 33.3 % of invasive ones showed p27 loss. Noninvasive tumor architecture also correlated with subsequent bladder carcinoma development (p = 0.032) while invasive tumor architecture correlated with advanced stage (T3 and T4) (p = 0.003). p27 is widely expressed in UUTUC, while p21 expression is observed in half of the cases. Loss of p27 expression correlated with tumor architecture and overall survival in UUTUC. However, further research is needed to assess their role in UUTUC.

Entities:  

Keywords:  Cylin-dependent kinase inhibitors; Prognosis; Upper tract urothelial carcinoma; Urinary tract; p21; p27

Mesh:

Substances:

Year:  2016        PMID: 27222134     DOI: 10.1007/s12253-016-0075-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.

Authors:  Gaëlle Fromont; Morgan Rouprêt; Najla Amira; Mathilde Sibony; Guy Vallancien; Pierre Validire; Olivier Cussenot
Journal:  Eur Urol       Date:  2005-08-01       Impact factor: 20.096

3.  Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

Authors:  A R Zlotta; J C Noel; I Fayt; A Drowart; J P Van Vooren; K Huygen; J Simon; C C Schulman
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

4.  Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.

Authors:  Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey K Ng; Mario Fernández; Theresa M Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

5.  Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.

Authors:  Jay D Raman; Casey K Ng; Douglas S Scherr; Vitaly Margulis; Yair Lotan; Karim Bensalah; Jean-Jacques Patard; Eiji Kikuchi; Francesco Montorsi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Theresa M Koppie; Hendrik Isbarn; Claudio Jeldres; Wareef Kabbani; Mesut Remzi; Mathias Waldert; Christopher G Wood; Marco Roscigno; Mototsuga Oya; Cord Langner; J Stuart Wolf; Philipp Ströbel; Mario Fernández; Pierre Karakiewcz; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2009-07-15       Impact factor: 20.096

6.  Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.

Authors:  Giacomo Novara; Vincenzo De Marco; Fedra Gottardo; Orietta Dalpiaz; Vianney Bouygues; Antonio Galfano; Guido Martignoni; Jean Jacques Patard; Walter Artibani; Vincenzo Ficarra
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

7.  Decreased p21 expression in HPV-18 positive cervical carcinomas.

Authors:  Lee-Wen Huang; Kok-Min Seow; Chin-Cheng Lee; Yu-Hung Lin; Hun-Shan Pan; Heng-Ju Chen
Journal:  Pathol Oncol Res       Date:  2009-08-06       Impact factor: 3.201

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.

Authors:  Jeannette Philipp-Staheli; Kyung-Hoon Kim; Denny Liggitt; Kay E Gurley; Gary Longton; Christopher J Kemp
Journal:  Oncogene       Date:  2004-01-29       Impact factor: 9.867

10.  Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

Authors:  S Clasen; W A Schulz; C D Gerharz; M O Grimm; F Christoph; B J Schmitz-Dräger
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

View more
  4 in total

1.  HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.

Authors:  Eva Juengel; Ramin Najafi; Jochen Rutz; Sebastian Maxeiner; Jasmina Makarevic; Frederik Roos; Igor Tsaur; Axel Haferkamp; Roman A Blaheta
Journal:  Oncotarget       Date:  2017-11-06

Review 2.  Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.

Authors:  Ricardo L Favaretto; Stênio C Zequi; Renato A R Oliveira; Thiago Santana; Walter H Costa; Isabela W Cunha; Gustavo C Guimarães
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

3.  Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.

Authors:  Saira Justin; Jochen Rutz; Sebastian Maxeiner; Felix K-H Chun; Eva Juengel; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

4.  Ubiquitin specific peptidase 19 is a prognostic biomarker and affect the proliferation and migration of clear cell renal cell carcinoma.

Authors:  Wenbing Hu; Yanfang Su; Xinxiong Fei; Xudong Wang; Guanglin Zhang; Chunyan Su; Tianxing Du; Tao Yang; Gangsheng Wang; Ze Tang; Jierong Zhang
Journal:  Oncol Rep       Date:  2020-03-26       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.